Session » 2017 Pediatric Rheumatology Symposium

2:00PM-3:00PM

Abstract Number: 3

Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study

2:00PM-3:00PM

Abstract Number: 4

Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome

2:00PM-3:00PM

Abstract Number: 2

Murine Model of Arthritis Flare Identifies CD8+ Tissue Resident Memory T Cells in Recurrent Synovitis

2:00PM-3:00PM

Abstract Number: 1

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis

4:45PM-5:15PM

Abstract Number: 15

An Internet-based Self-management Program for Adolescents with Juvenile Idiopathic Arthritis – A Randomized Controlled Trial

4:45PM-5:15PM

Abstract Number: 17

Anti-endothelial cell antibodies in juvenile dermatomyositis

4:45PM-5:15PM

Abstract Number: 18

Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen

4:45PM-5:15PM

Abstract Number: 24

Development and Implementation of a “Data-In-Once” Model for a Pediatric Rheumatology Learning Health System

4:45PM-5:15PM

Abstract Number: 14

Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial

4:45PM-5:15PM

Abstract Number: 21

Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health

4:45PM-5:15PM

Abstract Number: 20

Enthesitis-Related Arthritis: Non-Peripheral Pattern is Associated with an Expansion of Peripheral Th17 Populations

4:45PM-5:15PM

Abstract Number: 23

Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies

4:45PM-5:15PM

Abstract Number: 16

Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups

4:45PM-5:15PM

Abstract Number: 22

Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis

4:45PM-5:15PM

Abstract Number: 13

Prevalence of Celiac Antibodies and IgA deficiency in Juvenile Idiopathic Arthritis

4:45PM-5:15PM

Abstract Number: 25

Reliability of the Physician Global Assessment Scores for Determination of Disease Activity Status within the Pediatric Rheumatology Care and Outcomes Improvement Network

4:45PM-5:15PM

Abstract Number: 11

Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry

4:45PM-5:15PM

Abstract Number: 19

The Lymphocyte Repertoire in Juvenile Dermatomyositis

4:45PM-5:15PM

Abstract Number: 12

Use of Ultrasound to Determine Remission Status in Children with Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 154

“Celebrate Ability”: Structured Art Workshop as a Therapeutic Coping Strategy for Patients with Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 136

14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 133

3-D Explant Method Facilitates the Study of Lymphocytes in Synovium and Reveals a Population of Resident Memory-Like T Cells in Rheumatoid Arthritis

5:30PM-7:00PM

Abstract Number: 53

A Prospective Study to Assess for Changes in Mood with Initiation of Anti-TNF therapy: A Pilot Study

5:30PM-7:00PM

Abstract Number: 155

A Single Center Review of Health Related Quality of Life in Children with Systemic Lupus Erythematosus Using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scale

5:30PM-7:00PM

Abstract Number: 89

Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience

5:30PM-7:00PM

Abstract Number: 123

Acupuncture for Pediatric Chronic Pain Relief: A Review

5:30PM-7:00PM

Abstract Number: 146

Age-Related Differences in Neuronal High Mobility Group Box-1 and Resolvin D1 Receptors in Collagen-Induced Arthritis

5:30PM-7:00PM

Abstract Number: 134

Akkermansia Muciniphila May Be Permissive to Arthritis in the K/BxN Mouse Model of Arthritis

5:30PM-7:00PM

Abstract Number: 58

Analysis and Implications of Non-Invasive Knee Acoustical Emissions in Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 115

Anti-Phospholipid Antibodies in Children with Down Syndrome

5:30PM-7:00PM

Abstract Number: 76

Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome

5:30PM-7:00PM

Abstract Number: 116

Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study

5:30PM-7:00PM

Abstract Number: 87

Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis

5:30PM-7:00PM

Abstract Number: 106

Atypical manifestations and main misdiagnoses of Takayasu’s arteritis in childhood: a multicenter study of 71 patients

5:30PM-7:00PM

Abstract Number: 131

Balancing JAK/STAT-signaling with tofacitinib may foster anti-inflammatory functions of human monocytes

5:30PM-7:00PM

Abstract Number: 65

Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) –A Patient Reported Outcome

5:30PM-7:00PM

Abstract Number: 47

Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study

5:30PM-7:00PM

Abstract Number: 74

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

5:30PM-7:00PM

Abstract Number: 97

Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis

5:30PM-7:00PM

Abstract Number: 55

Celiac Disease in Children Diagnosed with Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 129

Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus

5:30PM-7:00PM

Abstract Number: 126

Challenges in Transitioning Adolescents with Rheumatologic Diseases to Adult Care – The Brazilian Experience

5:30PM-7:00PM

Abstract Number: 108

Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil

5:30PM-7:00PM

Abstract Number: 85

Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America

5:30PM-7:00PM

Abstract Number: 152

Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database

5:30PM-7:00PM

Abstract Number: 150

Childhood-onset Takayasu Arteritis Associated with Mutations in CBL

5:30PM-7:00PM

Abstract Number: 107

Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis

5:30PM-7:00PM

Abstract Number: 137

Chromatin Landscapes and Genetic Risk For Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 88

Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis

5:30PM-7:00PM

Abstract Number: 114

Clinical Features and Treatment Outcomes in Down’s Arthropathy

5:30PM-7:00PM

Abstract Number: 109

Clinical features of pediatric Behçet’s disease patients in Japan

5:30PM-7:00PM

Abstract Number: 71

Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany

5:30PM-7:00PM

Abstract Number: 98

Contraceptive use, Counseling given and the Occurrence of Venous Thrombus Embolism in Adolescent Systemic Lupus Erythematosus

5:30PM-7:00PM

Abstract Number: 96

Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index and Skindex-29 with Cutaneous Childhood Lupus Erythematous

5:30PM-7:00PM

Abstract Number: 93

Corticosteroid Regimen Use in the Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis

5:30PM-7:00PM

Abstract Number: 149

Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB1*15 and HLA-DRB1*03 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent

5:30PM-7:00PM

Abstract Number: 101

Defining Active Features of Juvenile Localized Scleroderma

5:30PM-7:00PM

Abstract Number: 127

Description of first 40 patients from a Rheumatologic Transition Clinic in Chile

5:30PM-7:00PM

Abstract Number: 95

Development of Cognitive Behavioral Therapy (CBT) for Childhood-onset Systemic Lupus Erythematosus (cSLE) Treatment

5:30PM-7:00PM

Abstract Number: 82

Disease Burden and Social Impact of Chronic Nonbacterial Osteomyelitis on Affected Children and Young Adults

5:30PM-7:00PM

Abstract Number: 102

Duration of High-Dose Aspirin Therapy Does Not Affect Coronary Artery Outcomes in Kawasaki Disease

5:30PM-7:00PM

Abstract Number: 139

Dysregulation of miRNA in mononuclear cells of patients with enthesitis related arthritis

5:30PM-7:00PM

Abstract Number: 77

Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study

5:30PM-7:00PM

Abstract Number: 94

Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)

5:30PM-7:00PM

Abstract Number: 111

Eosinophilic Fasciitis in Children: Clinical Course and Response to Treatment from Two Large Academic Centers

5:30PM-7:00PM

Abstract Number: 147

Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis

5:30PM-7:00PM

Abstract Number: 135

Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage

5:30PM-7:00PM

Abstract Number: 119

Establishment of registry for pediatric rheumatic diseases in Japan: Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey

5:30PM-7:00PM

Abstract Number: 64

Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 42

Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 113

Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis

5:30PM-7:00PM

Abstract Number: 141

Expression of Siglec-10 on Synovial Fluid CD14dim Monocytes Was Decreased in Juvenile Idiopathic Arthritis Patients

5:30PM-7:00PM

Abstract Number: 73

Factors Associated with Etoposide Usage in Children with Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 66

Feasibility Testing of An Internet-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents

5:30PM-7:00PM

Abstract Number: 75

Ferritin:ESR, A Predictor of MAS?

5:30PM-7:00PM

Abstract Number: 83

Feverprints: A Crowdsourcing Study of Temperature in Health and Disease

5:30PM-7:00PM

Abstract Number: 68

HLA-DRB1 in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis

5:30PM-7:00PM

Abstract Number: 125

How Do Health Literacy, Numeric Competencies and Patient Activation Impact Transition Readiness in Adolescents and Young Adults with Rheumatologic Diseases?

5:30PM-7:00PM

Abstract Number: 52

How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study

5:30PM-7:00PM

Abstract Number: 41

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 70

Impact of Systemic Juvenile Idiopathic Arthritis/Still’s Disease on Adolescents as Evidenced Through Social Media Posting

5:30PM-7:00PM

Abstract Number: 100

Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment

5:30PM-7:00PM

Abstract Number: 143

Influence of Age and Sex on Collagen-Induced Arthritis

5:30PM-7:00PM

Abstract Number: 132

Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study

5:30PM-7:00PM

Abstract Number: 105

Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis

5:30PM-7:00PM

Abstract Number: 145

JAK Inhibition Rescues Novel PSMB8 Mutations

5:30PM-7:00PM

Abstract Number: 144

Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 46

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis

5:30PM-7:00PM

Abstract Number: 44

Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study

5:30PM-7:00PM

Abstract Number: 48

Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry

5:30PM-7:00PM

Abstract Number: 138

Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 140

Modular Gene Expression Discrimination of Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Subphenotypes in Peripheral Blood

5:30PM-7:00PM

Abstract Number: 92

Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis

5:30PM-7:00PM

Abstract Number: 142

Neutrophils and monocytes in the early inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 62

Novel Approach to Quantifying Joint Pathology Via Musculoskeletal Ultrasound in Newly Diagnosed Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 148

Oral Microbial Profile in Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 118

Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease

5:30PM-7:00PM

Abstract Number: 60

Paediatric Arthritis Rehabilitation Exercise Study

5:30PM-7:00PM

Abstract Number: 49

Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 63

Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis

5:30PM-7:00PM

Abstract Number: 91

Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height

5:30PM-7:00PM

Abstract Number: 99

PILOT STUDY MEASURING HEPCIDIN AND ARTERIAL STIFFNESS IN CHILDREN WITH SLE AND LUPUS NEPHRITIS

5:30PM-7:00PM

Abstract Number: 79

Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases

5:30PM-7:00PM

Abstract Number: 84

Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

5:30PM-7:00PM

Abstract Number: 78

Predictors of Outcome Following Tonsillectomy in Periodic Fever, Aphthous Stomatitis Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome

5:30PM-7:00PM

Abstract Number: 159

Preferences and Satisfaction in a Pediatric Multi-specialty Infusion Center

5:30PM-7:00PM

Abstract Number: 81

Preliminary Consensus Treatment Plans for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis: The Foundation for Capturing Treatment Responses in PFAPA from the CARRA PFAPA Subcommittee

5:30PM-7:00PM

Abstract Number: 122

Presenting Manifestations of Amplified Musculoskeletal Pain Syndrome in Males versus Females

5:30PM-7:00PM

Abstract Number: 56

Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 158

Quality of Referral Letters to Pediatric Rheumatology and Its Impact on Access to Care

5:30PM-7:00PM

Abstract Number: 57

Quantification of Dynamic MRI examinations in Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 67

Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors

5:30PM-7:00PM

Abstract Number: 110

Risk Factors for Poor Health-Related Quality of Life in Children with Inflammatory Brain Diseases

5:30PM-7:00PM

Abstract Number: 90

Risk of Serious Infections in Juvenile Dermatomyositis patients treated with biological response modifiers including rituximab and abatacept

5:30PM-7:00PM

Abstract Number: 104

Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura

5:30PM-7:00PM

Abstract Number: 45

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease

5:30PM-7:00PM

Abstract Number: 121

Safety Of Biological Response Modifiers In Childhood Autoimmune Rheumatic Diseases From A Single North Indian Centre

5:30PM-7:00PM

Abstract Number: 151

Severe Phenotype of Mevalonate-kinase Deficiency in the Czech Republic

5:30PM-7:00PM

Abstract Number: 59

Six Minute Walk Test in Children with Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 160

Stepping Stones to Transition Smartly

5:30PM-7:00PM

Abstract Number: 72

Systemic Juvenile Idiopathic Arthritis in a Colombian cohort: onset and clinical course

5:30PM-7:00PM

Abstract Number: 156

Teaching High Value Musculoskeletal Care Through Online Simulation Cases

5:30PM-7:00PM

Abstract Number: 69

The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review

5:30PM-7:00PM

Abstract Number: 117

The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy

5:30PM-7:00PM

Abstract Number: 86

The myositis-specific autoantibody and myositis-associated autoantibody phenotypes in Japanese juvenile idiopathic inflammatory myopathies

5:30PM-7:00PM

Abstract Number: 103

The Performance of a New Risk Assessment Scoring System in Detecting IVIG Resistance in Kawasaki Disease as Compared to the Kobayashi and Egami Scores in a Large Single Centre Canadian Cohort

5:30PM-7:00PM

Abstract Number: 51

The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA

5:30PM-7:00PM

Abstract Number: 43

Tocilizumab Use in Pediatrics With Systemic Juvenile Idiopathic Arthritis: Single Center Data

5:30PM-7:00PM

Abstract Number: 153

Training pediatric rheumatology fellows intra-articular injection techniques and skills using a cadaver based musculoskeletal curriculum

5:30PM-7:00PM

Abstract Number: 54

Treatment and 1-year outcomes of an inception cohort of Australian children with JIA

5:30PM-7:00PM

Abstract Number: 80

Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades

5:30PM-7:00PM

Abstract Number: 128

Treatment Response in Polyarticular Juvenile Idiopathic Arthritis is Associated With Transcriptional Changes and Chromatin Reorganization in CD4+ T cells

5:30PM-7:00PM

Abstract Number: 50

Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients

5:30PM-7:00PM

Abstract Number: 124

Underutilization of Social Workers for Mental Health Care of Adolescents in Pediatric Rheumatology: A Mixed Methods Study

5:30PM-7:00PM

Abstract Number: 112

Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder

5:30PM-7:00PM

Abstract Number: 120

Use Of Thalidomide From A Tertiary Level Pediatric Rheumatology Centre In India

5:30PM-7:00PM

Abstract Number: 157

Utility of Mailed Reminders for Uveitis Screening Guidelines in Patients with Juvenile Idiopathic Arthritis

5:30PM-7:00PM

Abstract Number: 130

Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin

5:30PM-7:00PM

Abstract Number: 61

Which Juvenile Idiopathic Arthritis patient is more likely to have Temporomandibular Joint involvement?

2:00PM-3:00PM

Abstract Number: 7

Activation of Immature, Transitional B cells by Integrated BCR, TLR and TACI signals promotes systemic autoimmunity in high BAFF settings

2:00PM-3:00PM

Abstract Number: 5

Effects of Puberty on Systemic Lupus Erythematosus:  Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE

2:00PM-3:00PM

Abstract Number: 8

Examination of Reported Risk Loci from Candidate Gene Studies of Systemic Juvenile Idiopathic Arthritis Identifies Link between IL1RN Variation and both Disease Susceptibility and Response to Interleukin-1 Directed Therapy

2:00PM-3:00PM

Abstract Number: 6

High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth

2:30PM-3:00PM

Abstract Number: 9

Biologically-Based Approach for Classifying Chronic Childhood Arthritis

2:30PM-3:00PM

Abstract Number: 10

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88

5:15PM-5:45PM

Abstract Number: 33

An extracellular ionic milieu renders human granulocytic S100A12 into a pro-inflammatory TLR4-binding alarmin

5:15PM-5:45PM

Abstract Number: 27

Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythmatosus Patients

5:15PM-5:45PM

Abstract Number: 30

Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus

5:15PM-5:45PM

Abstract Number: 28

Dyslipidemia in Juvenile Dermatomyositis

5:15PM-5:45PM

Abstract Number: 26

Gray Matter Volume Loss in Youth with SLE

5:15PM-5:45PM

Abstract Number: 32

High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis

5:15PM-5:45PM

Abstract Number: 37

Increased Involvement of Teenagers with Juvenile Idiopathic Arthritis in Treatment Decisions Using Medication Choice Cards: Preliminary Report from a Case-Control Study

5:15PM-5:45PM

Abstract Number: 38

Knowledge Translation in Juvenile Idiopathic Arthritis Research in Canada: A Focus on Pediatric Rheumatologists and Allied Health Professionals

5:15PM-5:45PM

Abstract Number: 35

Kv1.3 Expression on Urinary Leukocytes in Lupus Nephritis:  Potential for Targeted Immunotherapy

5:15PM-5:45PM

Abstract Number: 40

Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit

5:15PM-5:45PM

Abstract Number: 31

Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search

5:15PM-5:45PM

Abstract Number: 39

Rheumapalooza:  A rheumatology curriculum in evolution

5:15PM-5:45PM

Abstract Number: 29

Spinal Cord Inflammation in Children with Small Vessel Primary CNS Vasculitis

5:15PM-5:45PM

Abstract Number: 36

The Association of Obesity with Pediatric Psoriatic Arthritis

5:15PM-5:45PM

Abstract Number: 34

The SLCO1B1 *14 Allele is Associated with Poor Response to Subcutaneous Methotrexate in Patients with Juvenile Idiopathic Arthritis